Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.
Vera Golder, Rangi Kandane-Rathnayake, Ning Li...
https://pubmed.ncbi.nlm.nih.gov/38876129/Actively Recruiting
Led by Monash University · Updated on 2024-12-12
5000
Participants Needed
20
Research Sites
261 weeks
Total Duration
Researchers are evaluating the Lupus Low Disease Activity State LLDAS in patients with Systemic Lupus Erythematosus SLE, a complex autoimmune disease affecting multiple organs and causing serious health problems. The study aims to see if achieving LLDAS is linked to better outcomes, including less organ damage, as traditional remission is rare and difficult to measure in lupus patients. The study is international and multi-center, led by the Asia Pacific Lupus Collaboration and sponsored by Monash University. Patients with SLE will be followed for approximately five years. During this time, researchers will collect regular data on disease activity and treatment to assess whether patients meet the LLDAS criteria. Annual assessments will also record lupus-related organ damage using the SLICC-ACR Damage Index and quality of life using the Short Form 36 version 2. At the end of the study, the researchers will evaluate if sustained LLDAS protects against organ damage. Participants will have their clinical and treatment data monitored regularly over several years. The study will measure outcomes including organ damage progression, quality of life, and mortality. These long-term assessments will help determine whether LLDAS is a useful target in managing lupus. The total participation time is about five to ten years, allowing detailed tracking of disease impact and patient well-being.
CONDITIONS
Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
E
Eric F Morand
R
Rangi K KANDANE-RATHNAYAKE
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Monash University
Lead Sponsor
Flinders Medical Centre, Adelaide, AUSTRALIA
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 5 years
Participants with Systemic Lupus Erythematosus (SLE) are followed over several years with regular data collection to assess disease activity, treatment, organ damage, and quality of life.
Regular visits for data collection over approximately 5 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Vera Golder, Rangi Kandane-Rathnayake, Ning Li...
https://pubmed.ncbi.nlm.nih.gov/38876129/Rangi Kandane-Rathnayake, Alberta Hoi, Worawit Louthrenoo...
https://pubmed.ncbi.nlm.nih.gov/41219118/Rangi Kandane-Rathnayake, Luigi Zolio, J Iyoon Choi...
https://pubmed.ncbi.nlm.nih.gov/41252474/Rangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo...
https://pubmed.ncbi.nlm.nih.gov/39656834/Vera Golder, Rangi Kandane-Rathnayake, Alberta Yik-Bun Hoi...
https://pubmed.ncbi.nlm.nih.gov/27829463/Vera Golder, Rangi Kandane-Rathnayake, Molla Huq...
https://pubmed.ncbi.nlm.nih.gov/38229349/Rangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo...
https://pubmed.ncbi.nlm.nih.gov/30398013/Rangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo...
https://pubmed.ncbi.nlm.nih.gov/38261390/Vera Golder, Molla Huq, Kate Franklyn...
https://pubmed.ncbi.nlm.nih.gov/28216192/Vera Golder, Rangi Kandane-Rathnayake, Alberta Yik-Bun Hoi...
https://pubmed.ncbi.nlm.nih.gov/28320433/Monash University
Lead Sponsor
Flinders Medical Centre, Adelaide, AUSTRALIA
Collaborating Sponsor